Adapsyn Bioscience: Pfizer, Genesys Invest in Natural-Product Drug Maker Adapsyn
Should Pfizer advance any potential compounds identified through the collaboration, Adapsyn is entitled to potential payments of up to $162 million.
Read full article »
Adapsyn is a Canada-based chemical bioinformatics platform that develops novel small molecule therapies for the treatment of patients with tuberculosis.
Read more